In Vitro Generation of Human XCR1(+) Dendritic Cells from CD34(+) Hematopoietic Progenitors
- PMID: 27142006
- DOI: 10.1007/978-1-4939-3606-9_2
In Vitro Generation of Human XCR1(+) Dendritic Cells from CD34(+) Hematopoietic Progenitors
Abstract
Dendritic cells (DCs) are a heterogeneous population of professional antigen-presenting cells which play a key role in orchestrating immune defenses. Most of the information gained on human DC biology was derived from studies conducted with DCs generated in vitro from peripheral blood CD14(+) monocytes (MoDCs) or from CD34(+) hematopoietic progenitors. Recent advances in the field revealed that these types of in vitro-derived DCs strikingly differ from the DC subsets that are naturally present in human lymphoid organs, in terms of global gene expression, of specialization in the sensing of different types of danger signals, and of the ability to polarize T lymphocytes toward different functions. Major efforts are being made to better characterize the biology and the functions of lymphoid organ-resident DC subsets in humans, as an essential step for designing innovative DC-based vaccines against infections or cancers. However, this line of research is hampered by the low frequency of certain DC subsets in most tissues, their fragility, and the complexity of the procedures necessary for their purification. Hence, there is a need for robust procedures allowing large-scale in vitro generation of human DC subsets, under conditions allowing their genetic or pharmacological manipulation, to decipher their functions and their molecular regulation. Human CD141(+)CLEC9A(+)XCR1(+) DCs constitute a very interesting DC subset for the design of immunotherapeutic treatments against infections by intracellular pathogens or against cancer, because these cells resemble mouse professional cross-presenting CD8α(+)Clec9a(+)Xcr1(+) DCs. Human XCR1(+) DCs have indeed been reported by several teams to be more efficient than other human DC subsets for cross-presentation, in particular of cell-associated antigens but also of soluble antigens especially when delivered into late endosomes or lysosomes. However, human XCR1(+) DCs are the rarest and perhaps the most fragile of the human DC subsets and hence the most difficult to study ex vivo. Here, we describe a protocol allowing simultaneous in vitro generation of human MoDCs and XCR1(+) DCs, which will undoubtedly be extremely useful to better characterize the functional specialization of human XCR1(+) DCs and to identify its molecular bases.
Keywords: CD34+ hematopoietic stem cells; Cross-presentation; Differentiation; Human immune system; Monocyte-derived dendritic cells; XCR1+ dendritic cells.
Similar articles
-
Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells.J Immunol. 2014 Aug 15;193(4):1622-35. doi: 10.4049/jimmunol.1401243. Epub 2014 Jul 9. J Immunol. 2014. PMID: 25009205 Free PMC article.
-
Human CD141+ dendritic cells generated from adult peripheral blood monocytes.Cytotherapy. 2019 Oct;21(10):1049-1063. doi: 10.1016/j.jcyt.2019.07.007. Epub 2019 Aug 23. Cytotherapy. 2019. PMID: 31447319
-
Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells.J Immunol. 2004 Aug 15;173(4):2780-91. doi: 10.4049/jimmunol.173.4.2780. J Immunol. 2004. PMID: 15294997
-
BDCA3(+)CLEC9A(+) human dendritic cell function and development.Semin Cell Dev Biol. 2015 May;41:39-48. doi: 10.1016/j.semcdb.2014.05.016. Epub 2014 Jun 6. Semin Cell Dev Biol. 2015. PMID: 24910448 Review.
-
New generation of dendritic cell vaccines.Hum Vaccin Immunother. 2013 Feb;9(2):259-64. doi: 10.4161/hv.22487. Epub 2013 Jan 4. Hum Vaccin Immunother. 2013. PMID: 23291951 Free PMC article. Review.
Cited by
-
Guidelines for mouse and human DC generation.Eur J Immunol. 2023 Nov;53(11):e2249816. doi: 10.1002/eji.202249816. Epub 2022 Oct 27. Eur J Immunol. 2023. PMID: 36303448 Free PMC article.
-
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.Cancer Commun (Lond). 2024 Sep;44(9):1047-1070. doi: 10.1002/cac2.12596. Epub 2024 Jul 25. Cancer Commun (Lond). 2024. PMID: 39051512 Free PMC article. Review.
-
Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.Curr Opin Immunol. 2017 Aug;47:35-43. doi: 10.1016/j.coi.2017.06.003. Epub 2017 Jul 18. Curr Opin Immunol. 2017. PMID: 28732279 Free PMC article. Review.
-
Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy.Oncoimmunology. 2019 May 1;8(8):1608106. doi: 10.1080/2162402X.2019.1608106. eCollection 2019. Oncoimmunology. 2019. PMID: 31413918 Free PMC article.
-
Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment.Cancers (Basel). 2021 Jan 23;13(3):433. doi: 10.3390/cancers13030433. Cancers (Basel). 2021. PMID: 33498755 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials